Holen Sie sich die Stockscreener-App
0.1033
17.75%
-0.0223
Handel nachbörslich:
.10
-0.0033
-3.19%
Schlusskurs vom Vortag:
$0.1256
Offen:
$0.1184
24-Stunden-Volumen:
84.69M
Relative Volume:
2.37
Marktkapitalisierung:
$14.30M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-27.39M
KGV:
-0.0615
EPS:
-1.6803
Netto-Cashflow:
$-2.09M
1W Leistung:
-21.68%
1M Leistung:
+13.52%
6M Leistung:
-67.01%
1J Leistung:
+0.00%
1-Tages-Spanne:
$0.09
$0.1184
1-Wochen-Bereich:
$0.09
$0.171
52-Wochen-Spanne:
$0.0709
$2.10
Aspire Biopharma Holdings Inc Stock (ASBP) Company Profile
Firmenname
Aspire Biopharma Holdings Inc
Sektor
Branche
Telefon
561-704-8527
Adresse
23150 FASHION DRIVE, SUITE 232, ESTERO
Vergleichen Sie ASBP mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ASBP
Aspire Biopharma Holdings Inc
|
0.1033 | 17.39M | 0 | -27.39M | -2.09M | -1.6803 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.68 | 122.84B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
801.01 | 85.37B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
399.40 | 55.82B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
795.57 | 50.67B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
170.27 | 37.54B | 447.02M | -1.18B | -906.14M | -6.1812 |
Aspire Biopharma Holdings Inc Aktie (ASBP) Neueste Nachrichten
FDA feedback clears path for Aspire Biopharma’s heart attack drug By Investing.com - Investing.com Nigeria
12 Health Care Stocks Moving In Wednesday's After-Market Session - Benzinga
ASBP Stock Soars 32% After Favorable Feedback From FDA For Its Aspirin – Retail Expects Licensing Negotiations Soon - Stocktwits
Aspire Biopharma stock soars after FDA meeting clears path for heart attack drug By Investing.com - Investing.com South Africa
Aspire Biopharma stock soars after FDA meeting clears path for heart attack drug - Investing.com Canada
FDA feedback clears path for Aspire Biopharma’s heart attack drug - Investing.com India
Aspire Biopharma Announces Successful Pre-IND Meeting with FDA for High-Dose Sublingual Aspirin (OTASA) - ACCESS Newswire
FDA backs trial of faster-acting aspirin powder for heart attacks - Stock Titan
Aspire Biopharma Provides Q3 2025 Business Update - Naples Daily News
Aspire Biopharma (ASBP) Competitors and Alternatives 2026 - MarketBeat
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
Aspire Biopharma Restructures Debt via Equity Exchange Agreements - TipRanks
Aspire Biopharma Holdings Signs Debt-for-Equity Exchange Agreements With Certain Debt Holders - TradingView — Track All Markets
Aspire Biopharma Granted Extension by Nasdaq Hearing Panel to Regain Compliance with Continued Listing Requirements - Asbury Park Press
Aspire Biopharma Submits Pre-IND Meeting Request and Briefing Package to U.S. FDA for Sublingual Aspirin Product for Treatment of Suspected Acute Myocardial Infarction (Heart Attack) - The Coloradoan
12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session - Benzinga
Aspire Biopharma Holdings, Inc. Announces CEO Transition - aberdeennews.com
Aspire BioPharma Welcomes Dr. Mark J. Jaroszeski as New Scientific Team Member - Petoskey News-Review
Aspire Biopharma Holdings, Inc., Announces Last Patient Dosed in Phase 1 Clinical Trial of its Oral Transmucosal Fast-Acting High-Dose Aspirin Formulation - Pensacola News Journal
Aspire Biopharma Holdings, Inc. Warrant 2025-18.02.30 on Aspire Bio Hldgs Revenue Breakdown – NASDAQ:ASBPW - TradingView — Track All Markets
Aspire Biopharma Holdings, Inc. Warrant 2025-18.02.30 on Aspire Bio Hldgs - TradingView — Track All Markets
Aspire Biopharma Engages with Global Pharmaceutical Leaders at CPHI Frankfurt to Advance Partnership Discussions for its Sublingual High-Dose Aspirin - Bluffton Today
Aspire Biopharma Welcomes Elite Ultra-Runner Ashley Paulson as Global Brand Ambassador for BUZZ BOMB(R) Caffeine - The Florida Times-Union
ASBPAI Stock Analysis - Meyka
Aspire Biopharma welcomes Ashley Paulson as Brand Ambassador - Comunicaffe International
Aspire Biopharma Welcomes Elite Ultra-Runner Ashley Paulson as Gl - The National Law Review
12 Health Care Stocks Moving In Thursday's After-Market Session - Benzinga
Aspire Biopharma names Ashley Paulson BUZZ BOMB global brand ambassador - TipRanks
Aspire Biopharma Holdings (ASBP) Stock on Dec. 15, 2025: Nasdaq Extension, FDA Pre‑IND Momentum, and Dilution Risks Investors Are Watching - ts2.tech
Finanzdaten der Aspire Biopharma Holdings Inc-Aktie (ASBP)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.80%
4.63%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):